Evidence map›Paper›PMID 39005294›Full record

ArticlebioRxiv : the preprint server for biology2024

EstroGene2.0: A multi-omic database of response to estrogens, ER-modulators, and resistance to endocrine therapies in breast cancer.

Zheqi Li, Fangyuan Chen, Li Chen, Jiebin Liu, Danielle Tseng, Fazal Hadi, Soleilmane Omarjee, Kamal Kishore, Joshua Kent, Joanna Kirkpatrick and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Zheqi LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1213-640X
Fangyuan ChenSchool of Medicine, Tsinghua University, Beijing, China.
Li ChenComputational Biology Department, Carnegie Mellon University, Pittsburgh PA, USA.
Jiebin LiuWomen's Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh PA, USA.
Danielle TsengWomen's Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh PA, USA.
Fazal HadiAstraZeneca, UK, London, UK.
Soleilmane OmarjeeCancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.
Kamal KishoreCancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.
Joshua KentCancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.
Joanna KirkpatrickCancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.
Clive D'SantosCancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.
Mandy LawsonAstraZeneca, UK, London, UK.
Jason GertzDepartment of Oncological Sciences, University of Utah, Salt Lake City, UT, USA.
Matthew J SikoraDepartment of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0003-2915-7442
Donald P McDonnellDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA.
Jason S CarrollCancer Research UK, Cambridge Institute, University of Cambridge, Cambridge, UK.
Kornelia PolyakDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Steffi OesterreichWomen's Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh PA, USA.
Adrian V LeeWomen's Cancer Research Center, UPMC Hillman Cancer Center, Pittsburgh PA, USA.ORCID 0000-0001-9917-514X

Funding

Manipulating normal estrogen physiology as a therapeutic approach in cancerR01CA276089 · NCI · DUKE UNIVERSITY · 2023 to 2025
$1.1M
MDC1: central regulator of estrogen receptor function and therapy response in lobular carcinomaR01CA251621 · UNIVERSITY OF COLORADO DENVER · 2025 to 2025
$711k
NCI NIH HHS R01 CA221303NCI NIH HHS R01 CA251621NCI NIH HHS R01 CA276089
6 · The paper itself

Abstract

Endocrine therapies targeting the estrogen receptor (ER/

Indexed as

Breast CancerDatabaseEndocrine ResistanceEstrogen ReceptorNGS Profiling

Identifiers

PMID39005294
PMCPMC11244912

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.